These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 27910026)

  • 1. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
    Wall M
    Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
    Mecucci C
    Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.
    Ronaghy A; Yang RK; Khoury JD; Kanagal-Shamanna R
    Curr Hematol Malig Rep; 2020 Jun; 15(3):194-202. PubMed ID: 32382988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress of cytogenetic detection in myelodysplastic syndromes].
    Zhou QB; Hu XM; Liu -; Ma R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1536-40. PubMed ID: 22169320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes.
    Wang J; Ai X; Qin T; Xu Z; Zhang Y; Liu J; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Cai W; Ru K; Jia Y; Huang G; Xiao Z
    Oncotarget; 2017 Jan; 8(1):1603-1612. PubMed ID: 27906673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes.
    Qin Y; Zhang H; Feng L; Wei H; Wu Y; Jiang C; Xu Z; Zhu H; Liu T
    Ann Med; 2022 Dec; 54(1):2627-2636. PubMed ID: 36148999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytogenetics of myelodysplastic syndromes and its impact as prognostic factor].
    Borjas-Gutiérrez C; Domínguez-Cruz MD; González-García JR
    Rev Med Inst Mex Seguro Soc; 2017; 55(4):481-489. PubMed ID: 28591503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes.
    Nomdedeu M; Calvo X; Pereira A; Carrió A; Solé F; Luño E; Cervera J; Vallespí T; Muñoz C; Gómez C; Arias A; Such E; Sanz G; Grau J; Insunza A; Calasanz MJ; Ardanaz MT; Hernández-Rivas JM; Azaceta G; Álvarez S; Sánchez J; Martín ML; Bargay J; Gómez V; Cervero CJ; Allegue MJ; Collado R; Campo E; Esteve J; Nomdedeu B; Costa D;
    Genes Chromosomes Cancer; 2016 Apr; 55(4):322-7. PubMed ID: 26690722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
    Auger N; Douet-Guilbert N; Quessada J; Theisen O; Lafage-Pochitaloff M; Troadec MB
    Curr Res Transl Med; 2023; 71(4):103409. PubMed ID: 38091642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group.
    Nomdedeu M; Pereira A; Calvo X; Colomer J; Sole F; Arias A; Gomez C; Luño E; Cervera J; Arnan M; Pomares H; Ramos F; Oiartzabal I; Espinet B; Pedro C; Arrizabalaga B; Blanco ML; Tormo M; Hernandez-Rivas JM; Díez-Campelo M; Ortega M; Valcárcel D; Cedena MT; Collado R; Grau J; Granada I; Sanz G; Campo E; Esteve J; Costa D;
    Leuk Res; 2017 Dec; 63():85-89. PubMed ID: 29121539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
    Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates in cytogenetics and molecular markers in MDS.
    Tiu RV; Visconte V; Traina F; Schwandt A; Maciejewski JP
    Curr Hematol Malig Rep; 2011 Jun; 6(2):126-35. PubMed ID: 21340513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
    Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
    Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytogenetic abnormalities of 50 MDS patients by FISH detection and conventional karyotype analysis].
    Gao DG; Li BT; Zhou LN; Chen H; Zhang B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1190-4. PubMed ID: 24156432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on cytogenetic and molecular changes in myelodysplastic syndromes.
    Schlegelberger B; Göhring G; Thol F; Heuser M
    Leuk Lymphoma; 2012 Apr; 53(4):525-36. PubMed ID: 21877899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic Syndrome in Pakistan: Clinicohematological Characteristics, Cytogenetic Profile, and Risk Stratification.
    Mahmood R; Altaf C; Ahmed P; Khan SA; Malik HS
    Turk J Haematol; 2018 May; 35(2):109-115. PubMed ID: 28588002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
    Padron E; Steensma DP
    Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.